Search hospitals > Pennsylvania > Pittsburgh
Allegheny General Hospital
Claim this profilePittsburgh, Pennsylvania 15212
Global Leader in High Blood Pressure
Global Leader in Breast Cancer
Conducts research for Pulmonary Hypertension
Conducts research for Parotid Gland Cancer
Conducts research for Pulmonary Arterial Hypertension
473 reported clinical trials
61 medical researchers
Summary
Allegheny General Hospital is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of High Blood Pressure, Breast Cancer, Pulmonary Hypertension, Parotid Gland Cancer, Pulmonary Arterial Hypertension and other specialties. Allegheny General Hospital is involved with conducting 473 clinical trials across 698 conditions. There are 61 research doctors associated with this hospital, such as Thomas Krivak, Gene G. Finley, Sarah Crafton, and Dulabh Monga, MD.Area of expertise
1High Blood Pressure
Global Leader2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Thomas KrivakWest Penn Hospital6 years of reported clinical research
Expert in Ovarian Cancer
Studies Parotid Gland Cancer
14 reported clinical trials
36 drugs studied
Gene G. FinleyAllegheny General Hospital10 years of reported clinical research
Studies Colon Cancer
Studies Lung Cancer
12 reported clinical trials
41 drugs studied
Sarah CraftonWest Penn Hospital5 years of reported clinical research
Studies Ovarian Cancer
Studies Parotid Gland Cancer
13 reported clinical trials
22 drugs studied
Dulabh Monga, MDAllegheny General Hospital5 years of reported clinical research
Studies Pancreatic Cancer
Studies Liver Cancer
10 reported clinical trials
29 drugs studied
Clinical Trials running at Allegheny General Hospital
Lung Cancer
Breast Cancer
Bladder Cancer
Liver Cancer
Bladder Carcinoma
Parotid Gland Cancer
Skin Cancer
Cardiovascular Disease
Cancer
Squamous Cell Carcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
BAY2927088
for Non-Small Cell Lung Cancer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments: * BAY 2927088 twice every day as a tablet by mouth, or * Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will: * take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer * check the overall health of the participants by performing tests such as blood and urine tests, and checking * heart health using an electrocardiogram (ECG) * perform pregnancy tests for women * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Recruiting2 awards Phase 33 criteria
Acasunlimab + Pembrolizumab
for Lung Cancer
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic setting.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Allegheny General Hospital?
Where is Allegheny General Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Allegheny General Hospital accept?
What awards or recognition has Allegheny General Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.